Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Orthofix Medical (OFIX) Research & Development (2016 - 2026)

Orthofix Medical has reported Research & Development over the past 17 years, most recently at $15.3 million for Q1 2026.

  • For the quarter ending Q1 2026, Research & Development fell 22.49% year-over-year to $15.3 million, compared with a TTM value of $61.4 million through Mar 2026, down 16.93%, and an annual FY2025 reading of $65.8 million, down 10.59% over the prior year.
  • Research & Development came in at $15.3 million for Q1 2026, roughly flat from $15.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $23.3 million in Q1 2023 to a low of $11.2 million in Q1 2022.
  • Median Research & Development over the past 5 years was $17.3 million (2024), compared with a mean of $16.7 million.
  • The sharpest move saw Research & Development surged 107.88% in 2023, then dropped 22.49% in 2026.
  • Over 5 years, Research & Development stood at $13.2 million in 2022, then skyrocketed by 44.02% to $18.9 million in 2023, then fell by 0.7% to $18.8 million in 2024, then decreased by 18.26% to $15.4 million in 2025, then decreased by 0.34% to $15.3 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's Research & Development are $15.3 million (Q1 2026), $15.4 million (Q4 2025), and $14.8 million (Q3 2025).